Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Neuroscience. 2012 May 17;210:451-66. doi: 10.1016/j.neuroscience.2012.02.038. Epub 2012 Feb 28.
Epileptogenesis following traumatic brain injury (TBI) is likely due to a combination of increased excitability, disinhibition, and increased excitatory connectivity via aberrant axon sprouting. Targeting these pathways could be beneficial in the prevention and treatment of posttraumatic epilepsy. Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein. LCM inhibited CRMP2-mediated neurite outgrowth, an effect phenocopied by CRMP2 knockdown. Mutation of LCM-binding sites in CRMP2 reduced the neurite inhibitory effect of LCM by ∼8-fold. LCM also reduced CRMP2-mediated tubulin polymerization. Thus, LCM selectively impairs CRMP2-mediated microtubule polymerization, which underlies its neurite outgrowth and branching. To determine whether LCM inhibits axon sprouting in vivo, LCM was injected into rats subjected to partial cortical isolation, an animal model of posttraumatic epileptogenesis that exhibits axon sprouting in cortical pyramidal neurons. Two weeks following injury, excitatory synaptic connectivity of cortical layer V pyramidal neurons was mapped using patch clamp recordings and laser scanning photostimulation of caged glutamate. In comparison with injured control animals, there was a significant decrease in the map size of excitatory synaptic connectivity in LCM-treated rats, suggesting that LCM treatment prevented enhanced excitatory synaptic connectivity due to posttraumatic axon sprouting. These findings suggest, for the first time, that LCM's mode of action involves interactions with CRMP2 to inhibit posttraumatic axon sprouting.
创伤性脑损伤(TBI)后的癫痫发生可能是由于兴奋性增加、抑制作用丧失以及异常轴突发芽导致兴奋性连接增加所致。针对这些途径可能有益于预防和治疗创伤后癫痫。在这里,我们使用新型抗惊厥药(R)-N-苄基 2-乙酰氨基-3-甲氧基丙酰胺((R)-拉科酰胺[LCM])测试了这种可能性,该药物作用于电压门控钠通道和 collapsin 反应介质蛋白 2(CRMP2),一种轴突生长/导向蛋白。LCM 抑制 CRMP2 介导的神经突生长,这一效应可被 CRMP2 敲低模拟。CRMP2 中 LCM 结合位点的突变使 LCM 对神经突的抑制作用降低了约 8 倍。LCM 还减少了 CRMP2 介导的微管聚合。因此,LCM 选择性地损害了 CRMP2 介导的微管聚合,这是其神经突生长和分支的基础。为了确定 LCM 是否在体内抑制轴突发芽,将 LCM 注射到部分皮质分离的大鼠中,这是一种表现出皮质锥体神经元轴突发芽的创伤后癫痫发生的动物模型。损伤后 2 周,使用膜片钳记录和笼状谷氨酸的激光扫描光刺激来映射皮质第 V 层锥体神经元的兴奋性突触连接。与受伤对照动物相比,LCM 处理大鼠的兴奋性突触连接图大小明显减小,表明 LCM 处理可防止创伤后轴突发芽引起的兴奋性突触连接增强。这些发现首次表明,LCM 的作用模式涉及与 CRMP2 的相互作用,以抑制创伤后轴突发芽。